MedTrace Logo

Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma

NCT03488667 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-05-19

No results posted yet for this study

Summary

To evaluate the antitumor activity and safety/tolerability of the combination (mFOLFOX + Pembrolizumab) in patients with potentially resectable adenocarcinoma of the Gastroesophageal Junction (GEJ) and stomach.

Conditions

  • Gastro Esophageal Junction Cancer
  • Stomach Cancer
  • Adenocarcinoma

Interventions

DRUG

Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab

Pembrolizumab, mFOLFOX Chemotherapy

DRUG

Adjuvant Treatment - mFOLFOX & Pembrolizumab

Pembrolizumab, mFOLFOX Chemotherapy

Sponsors & Collaborators

Principal Investigators

  • Weijing Sun, MD, FACP · The University of Kansas - Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-27
Primary Completion
2024-04-30
Completion
2025-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03488667 on ClinicalTrials.gov